Seaport Therapeutics, Inc. Common Stock Asset Resilience Ratio
Seaport Therapeutics, Inc. Common Stock asset resilience ratio. Seaport Therapeutics, Inc. Common Stock (SPTX) has an Asset Resilience Ratio of 47.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SPTX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Seaport Therapeutics, Inc. Common Stock (2024–2025)
Asset resilience ratio of Seaport Therapeutics, Inc. Common Stock from 2024 to 2025. This chart shows how Seaport Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read Seaport Therapeutics, Inc. Common Stock (SPTX) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Seaport Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SPTX asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $209.09 Million | 47.34% |
| Total Liquid Assets | $209.09 Million | 47.34% |
Asset Resilience Insights
- Very High Liquidity: Seaport Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 47.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Seaport Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Seaport Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Seaport Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2024–2025)
Seaport Therapeutics, Inc. Common Stock asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for Seaport Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 68.25% | $169.94 Million | $249.01 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $315.78 Million | -- |
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-30… Read more